143 / 1631
Conclusions (2)
•
Evidence of synergy between RT and checkpoint inhibition is strong in
preclinical lymphoma models with “high” T cell infiltrates or
immunologically “hot” tumours
•
Studies in HL of RT and anti-PD1 mAb underway
•
Studies in NHL of RT and other immunoregulatory agents ongoing
•
Currently there are opportunities to exploit the potential of RT and
immunoregulatory agents in other lymphomas
•
Need well planned studies with high quality RTQA and carefully record
efficacy and toxicity